Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
He has been associated with the Zydus Group since 2009
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
Subscribe To Our Newsletter & Stay Updated